IOVA IOVANCE BIOTHERAPEUTICS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1425205 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY51.3%
TTM net income YoY44.5%
TTM EPS YoY58.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin53.2%
Operating margin-60.8%
Net margin-58.2%
FCF margin-57.0%
EBITDA margin-54.0%
Returns
ROE-29.1%
ROA-23.3%
ROIC (approx.)-28.0%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets18.0%
Debt / equity0.00x
Current ratio5.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue6.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $263.50M | $164.07M | $1.19M | — | — |
| Cost of revenue | $173.18M | $93.25M | $1.03M | — | — |
| Gross profit | $90.32M | $70.82M | $156,000 | — | — |
| R&D expense | $300.27M | $276.23M | $333.19M | $294.78M | $259.04M |
| SG&A expense | $152.32M | $152.27M | $106.10M | $104.10M | $83.66M |
| Operating income | -$403.36M | -$395.28M | -$460.56M | -$398.88M | -$342.70M |
| Pretax income | -$393.05M | -$375.00M | -$447.52M | -$395.89M | -$342.25M |
| Income tax | -$2.07M | -$2.83M | -$3.48M | $0 | $0 |
| Net income | -$390.98M | -$372.18M | -$444.04M | -$395.89M | -$342.25M |
| EBITDA | -$390.49M | -$384.02M | -$448.99M | -$389.57M | -$339.59M |
| EPS (basic) | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
| EPS (diluted) | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
| Weighted avg. shares (diluted) | 357,345 | 289,877 | 235,131 | 159,259 | 153,406 |
| Balance sheet | |||||
| Cash & equivalents | $163.08M | $122.05M | $114.89M | $238.16M | $84.31M |
| Short-term investments | $133.90M | $208.09M | $164.98M | $240.11M | $426.18M |
| Receivables | $82.45M | $69.34M | $151,000 | — | — |
| Inventory | $51.68M | $51.52M | $10.37M | — | — |
| Current assets | $442.69M | $457.02M | $307.85M | $479.12M | $507.96M |
| PP&E, net | $131.11M | $109.08M | $114.03M | $105.23M | $100.94M |
| Intangibles | $279.32M | $282.40M | $229.26M | — | — |
| Total assets | $913.17M | $910.43M | $780.35M | $663.98M | $777.33M |
| Current liabilities | $138.36M | $122.34M | $110.31M | $91.48M | $89.20M |
| Total liabilities | $214.59M | $200.02M | $195.74M | $164.34M | $155.67M |
| Shareholders' equity | $698.58M | $710.40M | $584.61M | $499.64M | $621.66M |
| Shares outstanding | 411.94M | 305.25M | 256.14M | 187.81M | 157.00M |
| Cash flow statement | |||||
| Operating cash flow | -$302.41M | -$352.98M | -$361.82M | -$292.76M | -$227.94M |
| Capital expenditure | $33.84M | $11.07M | $22.29M | $20.43M | $37.57M |
| Free cash flow | -$336.24M | -$364.05M | -$384.11M | -$313.18M | -$265.51M |
| Investing cash flow | $47.50M | -$96.41M | -$155.24M | $256.45M | $132,000 |
| Financing cash flow | $300.77M | $390.66M | $462.96M | $190.15M | $239.27M |
| Depreciation & amortization | $12.86M | $11.26M | $11.57M | $9.31M | $3.11M |
| Stock-based compensation | $61.58M | $109.63M | $62.62M | $84.02M | $69.77M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.